|
32 Companies |
|
48 Products |
|
48 Products |
|
52 Mechanisms of Action |
|
0 Trials |
|
99 News |
|
| «12 |
- | carboplatin / Generic mfg., cisplatin / Generic mfg., floxuridine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=45, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed
- | topotecan / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Combination therapy: Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=17, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Northwestern University
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Post-transplantation: Stem Cell Transplantation in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion, Gene therapy: Gene Therapy in Treating Patients With Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Roger Williams Medical Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=82, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Metastases: PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion, Metastases: Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity (clinicaltrials.gov) - Feb 19, 2014
P1, N=20, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=36, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | irinotecan / Generic mfg.
Trial completion: Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Interleukin-12 in Treating Patients With Cancer in the Abdomen (clinicaltrials.gov) - Feb 19, 2014
P1, N=29, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | phenobarbital / Generic mfg., cyclosporin A microemulsion / Generic mfg., irinotecan / Generic mfg.
Trial completion: Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=3, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed N=55 --> 43
- Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
N=55 --> 43 N=45 --> 34
- | Rytelo (imetelstat) / Geron
Trial completion: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
N=45 --> 34 Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial suspension: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=150, Suspended, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Suspended
- ||| melphalan / Generic mfg.
Enrollment change, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
Recruiting --> Suspended N=105 --> 56
- |||| melphalan / Generic mfg.
Trial completion, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
N=105 --> 56 Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Aug 18, 2013
P1, N=28, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Epigenetic controller: Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma (clinicaltrials.gov) - Jul 31, 2013
P1, N=23, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- levofloxacin / Generic mfg.
Trial completion: CRC-TU-SIGNIFICANT: Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma (clinicaltrials.gov) - Jul 31, 2013
P3, N=0, Completed, Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- picoplatin (AMD 473) / Accelerated Pharma
Trial completion, Metastases: ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 16, 2013
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial termination: Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract (clinicaltrials.gov) - May 14, 2013
P2, N=7, Terminated, Sponsor: The University of Texas, Galveston
Active, not recruiting --> Completed Completed --> Terminated; Administratively Terminated
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (clinicaltrials.gov) - Mar 19, 2013
P2, N=52, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated; Administratively Terminated N=102 --> 52
- oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Feb 17, 2013
P1, N=28, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
N=102 --> 52 N=22 --> 28
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: BMS-247550 in Treating Patients With Advanced Cancers (clinicaltrials.gov) - Feb 7, 2013
P1, N=54, Completed, Sponsor: National Cancer Institute (NCI)
N=22 --> 28 Active, not recruiting --> Completed
- Trial termination, Tumor cell: EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. Recruiting --> Active, not recruiting
- gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer (clinicaltrials.gov) - Nov 20, 2012
P1, N=16, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion, Metastases: S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction (clinicaltrials.gov) - Oct 30, 2012
P1, N=78, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed N=82 --> 25
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=82 --> 25 N=44 --> 132
- Trial completion: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=44 --> 132 Active, not recruiting --> Completed
- imatinib / Generic mfg.
Trial completion, Metastases: STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=91, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=115, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 20, 2012
P1, N=108, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=60 --> 32
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (clinicaltrials.gov) - Feb 21, 2012
P2, N=32, Completed, Sponsor: City of Hope Medical Center
N=60 --> 32 Active, not recruiting --> Completed
- || Enrollment closed, HEOR: Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer (clinicaltrials.gov) - Nov 28, 2011
P=N/A, N=132, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed, IO biomarker: Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma (clinicaltrials.gov) - Nov 22, 2011
P=N/A, N=31, Active, not recruiting, Sponsor: Craig Hofmeister
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Non-Ablative Allo HSCT For Hematologic Malignancies or SAA (clinicaltrials.gov) - Oct 12, 2011
P2, N=58, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, HEOR: Quality of Life in Younger Leukemia and Lymphoma Survivors (clinicaltrials.gov) - Aug 16, 2011
P1, N=48, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed